Browsing by Author Tebbutt, Niall C

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 16 of 16
Issue DateTitleAuthor(s)Citation
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2010Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study.Gebski, Val; Simes, Robert John; Stockler, Martin; Zannino, Diana; Ackland, Stephen P.; Broad, Adam; Chua, Yu Jo; Cummins, Michelle; Cunningham, David; Forgeson, Garry; Ganju, Vinod; Price, Timothy; Robinson, Bridget; Saunders, M; Tebbutt, Niall C; van Hazel, Guy; Wilson, Kate; Zalcberg, J; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCapecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study., Journal of Clinical Oncology (Online), vol.28, 19,pp 3191-3198
2007Cetuximab for the Treatment of Colorectal CancerSimes, Robert John; Zalcberg, John; Au, Heather Jane; Berry, Scott R.; et, al; Jonker, Derek J.; Karapetis, Christos (Chris); Krahn, Marianne; O’Callaghan, Chris J.; Price, Timothy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357,(20),2007,pp 2040-2048
2014The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX studyCarter, Hannah; Howard, Kirsten; Schofield, Deborah; Simes, Robert John; Zannino, Diana; Price, Timothy; Tebbutt, Niall C; Zalcberg, John; Anaesthesia; School of Public Health: Public Health; Pharmacy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study, European Journal of Cancer, vol.50, 3, 2014,pp 535-543
2013Current opinion on optimal treatment for colorectal cancerPavlakis, Nick; Ackland, Stephen P.; Burge, Matthew; Cunningham, David; Haller, Daniel; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, Jeremy; Sobrero, Alberto; Tebbutt, Niall C; Northern Clinical School: MedicineCurrent opinion on optimal treatment for colorectal cancer, Expert Review of Anticancer Therapy, vol.13, 5, 2013,pp 597-611
2013Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trialGebski, Val; Parry, M M; Pavlakis, Nick; Zannino, Diana; Dobrovic, Alexander N; Ganju, V.; Mellor, D; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreDocetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial, British Journal of Cancer, vol.108, 4, 2013,pp 771-774
2010Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomasBrown, Christopher; Gainford, Mary; Gebski, Val; Miller, Danielle; Abdi, Ehtesham A; Ackland, Stephen P.; Goldstein, D; Jefford, Michael; Selva-Nayagam, Sid; Shannon, Jenny; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreFixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas, Cancer Chemotherapy and Pharmacology, vol.0, 0,pp 1-7
2015Glycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory diseaseBao, Bob Shi San; Buchert, Michael; Burgess, A W; Doggett, Karen; et al, Various; hollande, Frederic; Johnstone, Cameron; Masson, Frederick; Putoczki, Tracy L; Scott, Andrew M; Tebbutt, Niall C; Williams, Benjamin B; School of Medical Sciences: PathologyGlycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory disease, Disease Models & Mechanisms, vol.8, 8, 2015,pp 805-815
2011Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerCummins, Michelle; Lee, Chee; Chua, Ann; Hardingham, Jennifer; Murone, Carmel; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Weikhardt, Andrew; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreImpact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.29, 19, 2011,pp 2675-2682
2013Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factorsClarke, Stephen; Pavlakis, Nick; Desai, Jayesh; Gibbs, Peter; Karapetis, Christos; Michael, Michael; Pricek, T.J.; Tabernero, Josep; Tebbutt, Niall C; Concord Clinical School: Medicine; Northern Clinical School: MedicineOverview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors, Critical Reviews in Oncology / Hematology (online), vol.85, 2, 2013,pp 121-135
2014PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17Simes, Robert John; Daneshmand, Manijeh; et al, Various; Hanson, Jennifer E; Jonker, Derek; Karapetis, Christos; Marginean, Celia; Moore, Malcolm J; OCallghan, Christopher J; Price, Timothy; Tebbutt, Niall C; Zalcberg, John R; School of Public Health: NH&MRC Clinical Trials CentrePIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer--Results from NCIC CTG/AGITG CO.17, Clinical Cancer Research, vol.20, 3, 2014,pp 744-753
2014Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerLee, Chee Khoon; Arentz, Georgia; Bruhn, Maressa; Cunningham, David; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreProangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer, International Journal of Cancer, vol.135, 3, 2014,pp 731-741
2010Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialCummins, Michelle; Gebski, Val; Sourjina, Tatiana; Stockler, Martin; Ganju, Vinod; Gibbs, David; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial, British Journal of Cancer, vol.102, 3,pp 475-481
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838
2014The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsPavlakis, Nick; Chan, D; Karapetis, Christos; Price, Timothy; Segelov, Eva; Shapiro, J; Tebbutt, Niall C; Northern Clinical School: MedicineThe role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials, British Journal of Cancer, vol.111, 6, 2014,pp 1122-1131
2011Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysisBoland, Amy L.; Brown, Christopher; Clarke, Stephen; Gebski, Val; Simes, Robert John; Yip, Sonia; Buck, M; Goldstein, David; Jeffrey, G. Mark; Lowenthal, Raymond M.; Ransom, David T.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSingle-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis, European Journal of Cancer, vol.47, 12, 2011,pp 1826-1836